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Abstract
Background—The feasibility of using health system data to estimate prevalence of chronic 
kidney disease (CKD) stages 3–5 was explored.
Study Design—Cohort study.
Setting & Participants—A 5% national random sample of patients from the Veterans Affairs 
(VA) health care system, enrollees in a managed care plan in Michigan (M-CARE), and 
participants from the 2005–2006 National Health and Nutrition Examination Survey (NHANES).
Address correspondence to Rajiv Saran, MBBS, MD, MRCP, MS, Division of Nephrology, Department of Internal Medicine, 
University of Michigan-Kidney Epidemiology and Cost Center, 1415 Washington Heights, Ste 3645, Ann Arbor, MI 48109-2029. 
rsaran@umich.edu.
*A list of the CDC CKD Surveillance System team appears in the Acknowledgements.
Financial Disclosure: The authors declare that they have no other relevant financial interests.
SUPPLEMENTARY MATERIAL
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Predictor—Observed CKD prevalence estimates in the health system population were calculated 
as patients with an available outpatient serum creatinine measurement with estimated glomerular 
filtration rate <60 mL/min/1.73 m2, among those with at least one outpatient visit during the year.
Outcomes & Measurements—A logistic regression model was fitted using data from the 
2005–2006 NHANES to predict CKD prevalence in those untested for serum creatinine in the 
health system population, adjusted for demographics and comorbid conditions. Model results then 
were combined with the observed prevalence in tested patients to derive an overall predicted 
prevalence of CKD within the health systems.
Results—Patients in the VA system were older, had more comorbid conditions, and were more 
likely to be tested for serum creatinine than those in the M-CARE system. Observed prevalences 
of CKD stages 3–5 were 15.6% and 0.9% in the VA and M-CARE systems, respectively. Using 
data from NHANES, the overall predicted prevalences of CKD were 20.4% and 1.6% in the VA 
and M-CARE systems, respectively.
Limitations—Health system data quality was limited by missing data for laboratory results and 
race. A single estimated glomerular filtration rate value was used to define CKD, rather than 
persistence over 3 months.
Conclusions—Estimation of CKD prevalence within health care systems is feasible, but 
discrepancies between observed and predicted prevalences suggest that this approach is dependent 
on data availability and quality of information for comorbid conditions, as well as the frequency of 
testing for CKD in the health care system.
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Chronic kidney disease (CKD) is now recognized as a major public health problem.2,3 It is 
associated with substantial morbidity and mortality and affects more than 20 million adults 
in the United States.4,5 Whereas national registries exist for patients requiring renal 
replacement therapy, no surveillance system has been available until recently for the much 
larger population with earlier forms of CKD.1 ACKD surveillance system ideally should be 
able to identify individuals with CKD and track the burden, or prevalence, of CKD in the 
nation as a whole, as well as in specific populations or geographic regions.
Although the National Health and Nutrition Examination Survey (NHANES) has been used 
effectively to estimate the national prevalence of CKD, lack of geographic granularity limits 
its utility for assessing prevalence within populations served by individual health care 
systems. Such information could be of great use for directing and monitoring quality 
improvement efforts in those populations. With the expansion of electronic medical records 
across the country, use of data from health care systems may represent an efficient approach 
to estimating the prevalence of CKD in those populations.6
As part of a US Centers for Disease Control and Prevention–sponsored project charged with 
developing a national surveillance system for CKD,1 we explored the feasibility of using 
health care system data to identify persons with CKD and produce estimates of CKD 
prevalence. We used 2 examples of health care system data, from a 5% national sample of 
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patients from the US Department of Veterans Affairs (VA) health care system and a regional 
managed care plan, and compared the results obtained with NHANES-derived estimates of 
prevalence in those populations.
METHODS
Data Sources/Study Participants
National Health and Nutrition Examination Survey—The NHANES program has 
been well described previously.7 Data used for this report were from the 2005–2006 survey 
and included information from participants 20 years or older. By design, all participants 
received testing for serum creatinine. Participants with missing data for serum creatinine (n 
= 270), who had received dialysis within 12 months of the survey (n = 16), or who were 
pregnant or menstruating at the time of examination (n = 440) were excluded. All analyses 
incorporated examination weights, strata, and pseudostrata to reflect the survey sample 
design.
VA Health System—The Veterans Health Administration is the largest integrated health 
care system in the United States. National data for VA patients are processed at the Austin 
Automation Center, Austin, TX, which abstracts information from VA facilities such as 
patient demographics, medical diagnoses and procedures, outpatient and inpatient visits, and 
vital status.8 The data files include the Medical SAS Datasets, which contain information for 
diagnoses and procedures using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) and Current Procedural Terminology coding systems. In 
addition, the VA Decision Support System files include pharmacy information and selected 
laboratory results. For this study, a 5% random sample of national VA data from fiscal year 
2005 was extracted. Although a linkage with VA data and Medicare claims is available, this 
was not used for this study to avoid limiting the population to older patients. For 
comparability with NHANES data, patients 20 years and older were included in the 
analyses, and patients with diagnosis or procedure codes indicating pregnancy, dialysis, or 
kidney transplantation were excluded. To ensure that patients were using the VA health care 
system, the cohort was limited further to individuals who had at least one outpatient visit to 
a VA facility in 2005.
M-CARE—M-CARE was a managed care health plan in the Southeast Michigan region that 
was owned and operated by the University of Michigan Health System until December 31, 
2006. M-CARE created and maintained a high-quality claims data repository that describes 
health care utilization since 1997 for its covered population. The database includes billing 
claims with diagnosis and procedure codes using the ICD-9-CM and Current Procedural 
Terminology systems, pharmacy data files, and laboratory results in a subset of patients. For 
comparability to the NHANES and VA health care system data sets, data from calendar year 
2005 were used, patients 20 years and older with at least one claim for an outpatient visit 
were selected, and those with diagnosis codes indicating dialysis, kidney transplantation, or 
pregnancy were excluded. A substantial proportion (49.7%) of patients had missing 
laboratory data (ie, a claim was present for serum creatinine testing, but no result was 
available). In the subset of patients who had a University of Michigan primary care 
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physician (UM-PCP), laboratory data were available more consistently (75% of cases with a 
claim for serum creatinine testing had a laboratory result). Results for M-CARE data were 
stratified accordingly by whether patients had a UM-PCP; characteristics of the groups were 
compared.
Definitions of Study Variables
Detailed descriptions for selected study variables are listed in Table S1 (provided as online 
supplementary material). The CKD Epidemiology Collaboration (CKD-EPI) creatinine 
equation was used for calculation of estimated glomerular filtration rate (eGFR; for 
comparison, results using the 4-variable Modification of Diet in Renal Disease Study 
equation are listed in Table S2).9 For this study, CKD then was defined as eGFR <60 
mL/min/1.73 m2 (ie, National Kidney Foundation–Kidney Disease Outcomes Quality 
Initiative [NKF-KDOQI]10 stages 3–5), excluding patients on dialysis therapy or after 
kidney transplantation. No attempt was made to identify CKD stages 1 or 2 because urine 
protein assessments were available infrequently in the VA and M-CARE data sets. For the 
VA and M-CARE data sets, only outpatient serum creatinine values were used to minimize 
misclassification of episodes of acute kidney injury as CKD. If multiple serum creatinine 
values were available in a year, a single value was randomly chosen. In the VA or M-CARE 
data only, CKD also was identified separately based on the presence of at least one inpatient 
or outpatient ICD-9-CM diagnosis code (see Table S1). The CKD diagnosis codes were 
selected based on previous literature and study team consensus.11,12
Relevant comorbid conditions identified in the data sets included diabetes mellitus, 
hypertension, and anemia. Race was classified in NHANES as non-Hispanic white, non-
Hispanic black, Mexican American, other Hispanic, and other. Although the National Center 
for Health Statistics recommends keeping the Hispanic categories separate, the other 
Hispanic and Mexican American categories were grouped together as Hispanic solely for 
purposes of comparisons with the VA data set. In the VA data set, race was classified as 
non-Hispanic white, non-Hispanic black, Hispanic, Asian, Pacific Islander, Native 
American, and other or unknown, with the latter 5 categories grouped under the heading 
other/unknown. Race was unavailable in the M-CARE database.
Statistical Analyses
Demographic information for each of the data sets was tabulated. The proportion of patients 
undergoing testing for serum creatinine within a year in the VA and M-CARE health care 
systems was estimated based on the availability of an actual laboratory result and/or the 
presence of an outpatient claim indicating serum creatinine testing.
The prevalence of CKD stages 3–5 was calculated in NHANES data with adjustment for 
sampling weights and the survey design. Prevalence of CKD From Health System Data In 
the case of VA and M-CARE data, observed prevalence was calculated as follows: the 
number of persons with CKD stages 3–5 divided by the number of persons within the health 
care system 20 years and older who had at least one outpatient visit during the 1-year study 
period. For the VA and M-CARE data sets, the prevalence of CKD based on claims alone or 
a combination of claims and eGFR also was calculated.
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When race information was missing for the VA and M-CARE data sets, eGFR was 
calculated using non-Hispanic white race as the default. To improve prevalence estimates 
when race information was missing, eGFRs also were calculated using a single imputation 
for black race based on the proportion of blacks in the zip code of residence of the patient 
(from the US Census7) as follows: the race coefficient in the CKD-EPI equation was 
calculated as 1 + (0.159 × proportion of blacks in zip code). To assess the validity of the 
imputation, a comparison was made between true CKD status (ie, eGFR ≥60 or <60 
mL/min/1.73 m2) and CKD status imputed by zip code–based race coefficient in the group 
of patients with known race. The κ statistic for the comparison was 0.99, suggesting 
excellent agreement between classifications of CKD based on actual race versus race from 
the zip code imputation.
Because the observed prevalence estimates in the health care systems were expected to be 
underestimates due to incomplete testing for serum creatinine, a logistic regression model 
was fitted using the NHANES data set to predict the presence of CKD stages 3–5 based on 
age, race (non-Hispanic black vs nonblack), diabetes mellitus, hypertension, anemia, and 
sex. The coefficients from this model then were applied to the subgroups of patients who did 
not undergo testing for serum creatinine within the VA and M-CARE data sets to produce 
estimates of the predicted prevalence of CKD stages 3–5 within the untested populations. 
These were combined with the observed prevalence estimates based on the tested 
populations to produce overall estimates of the predicted prevalence of CKD stages 3–5 
within the VA and M-CARE health care systems. To assess how well the model predicted 
CKD stages 3–5 within these health care systems, it also was applied to the subgroup that 
had undergone testing for serum creatinine in order to compare the predicted prevalence of 
CKD with the actual observed prevalence of CKD. Within NHANES data, the C statistic for 
the model was 0.92, with C statistics of 0.81 and 0.87 in the VA and M-CARE populations, 
respectively. Observed versus predicted prevalence in the tested VA and M-CARE 
populations across the full strata of patient clinical and demographic characteristics is listed 
in Table S3.
Because the VA data set contained a substantial proportion of patients with multiple serum 
creatinine values within a year, the stability of the CKD stage classification based on eGFR 
estimation was examined. Patients in the VA system with 2 available serum creatinine 
measurements 3–6 months apart were selected. CKD stage classification based on eGFR at 
the first measurement was cross-tabulated with CKD stage classification at the second 
measurement to determine the proportion of patients for whom CKD stage classification 
remained stable.
All analyses were performed with SAS, version 9.2 (SAS Institute Inc). The study protocol 
was approved by the institutional review boards of the University of Michigan and VA Ann 
Arbor Healthcare System.
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RESULTS
Comparison of Population Characteristics
Table 1 presents a comparison of population characteristics across the NHANES (ie, general 
United States), VA, and M-CARE data sets. Compared to the NHANES population, the VA 
system included a predominantly male, older population with a higher prevalence of 
comorbid conditions, such as diabetes mellitus and hypertension. The M-CARE population 
included a generally younger, healthier population.
Proportion of Patients Tested
The proportion of patients tested for serum creatinine was significantly higher in the VA 
system (75.8%) than in the M-CARE UM-PCP (36.6%) or non–UM-PCP (41.3%) 
populations (Table 2). In both the VA and M-CARE populations, testing increased with age 
and was higher in patients with diabetes mellitus or hypertension, with persisting differences 
between the VA and M-CARE systems. The proportion tested for albuminuria was very low 
regardless of health care system; 10.3% had measured albuminuria in the VA system (35.6% 
with diabetes and 14.1% with hypertension) and 6.0% had albuminuria measurement in the 
overall M-CARE population (45.2% in patients with diabetes and 17.1% in patients with 
hypertension).
Estimated CKD Stages 3–5 Prevalence in VA and M-CARE Systems
Table 3 lists observed estimates of the prevalence of CKD stages 3–5 in the NHANES, VA, 
and M-CARE (including only the subset with a UM-PCP) data sets. Observed prevalence 
was highest in the VA, intermediate in NHANES, and lowest in the M-CARE system. In all 
3 data sets, prevalence was higher with increasing age, presence of diabetes mellitus, and 
presence of hypertension. Imputation of race in the M-CARE and VA data sets led to a small 
reduction in the estimated prevalence of CKD stages 3–5 (ie, an increase in population mean 
eGFR) in the VA system only compared to the assumption that all patients with unknown 
race were white. CKD prevalence based on ICD-9-CM diagnosis claims alone produced 
substantially lower estimates than those based on eGFR calculation. A definition of CKD 
based on eGFR and/or diagnosis claims produced prevalence estimates slightly higher than 
for eGFR alone for both the VA and M-CARE data sets.
Figure 1 shows results for the VA and M-CARE health systems comparing the observed 
prevalence of CKD stages 3–5 versus the prevalence predicted based on a model using 
NHANES data. To evaluate how well the model predicted CKD stages 3–5 in the health 
care systems, the predicted and observed prevalences of CKD stages 3–5 initially were 
compared using only patients who had undergone testing for serum creatinine (Fig 1, left 
panel). The 2 estimates were virtually identical for the M-CARE data, but the predicted 
prevalence of CKD stages 3–5 was slightly higher than the observed prevalence within the 
VA data. There were substantial gaps in both the VA and M-CARE systems between 
observed and predicted prevalences in the overall population (Fig 1, right panel), with the 
observed prevalence being roughly two-thirds of the predicted prevalence.
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Stability of CKD Staging
Table 4 presents the stability of CKD staging by eGFR in the VA system among the subset 
of individuals who had 2 serum creatinine results available 3–6 months apart (n = 26,080; 
mean age, 66.1 years; diabetes, 39.6%; and hypertension, 83.0%). In those with an initial 
eGFR >60 mL/min/1.73 m2, >90% remained stable. For those with CKD stages 3–5 at 
initial assessment, two-thirds to three-quarters remained within the same classification at 
assessment 3–6 months later. In most cases in which stage classification was different, 
individuals were classified into a less severe stage (ie, with a higher eGFR). For example, in 
those initially classified with stage 3 CKD, 20% were classified as not having CKD on the 
basis of subsequent serum creatinine–based eGFR calculation.
DISCUSSION
This study assessed the feasibility of producing estimates of CKD prevalence using 
available data from a large national and a large regional health care system. A number of 
potential issues and challenges were identified. One major issue was the choice of 
denominator for the calculation of prevalence. In NHANES, all participants undergo testing 
for serum creatinine by design, allowing estimation of the “true prevalence” of CKD within 
the population. The numerator of the prevalence calculation includes persons with CKD and 
the denominator is simply the entire survey population (using appropriate survey weights 
when estimating national prevalence). When using health care system data, estimating 
prevalence is more complex because testing for serum creatinine generally is performed 
only for clinical indications. Using a denominator that includes only those tested, as some 
studies have done,13,14 therefore would tend to overestimate the true prevalence of CKD. 
We instead chose to use a denominator that included the entire population available (with 
noted exclusions) in the health care data set. However, the extent to which this prevalence 
approximates the “true prevalence” will depend on testing practices. In an idealized 
scenario, if untested persons were uniformly free of CKD, the prevalence of CKD as 
observed in the health care system data would equal the true prevalence of CKD in the 
population under consideration. To the extent that some persons with CKD are not tested, 
the prevalence based on health care system data would be an underestimate of the true 
prevalence. We used modeling based on NHANES data to assess the degree to which this 
underestimation occurred by examining the predicted prevalence of CKD in the untested 
populations of the health care systems. In the context of this study, the observed prevalence 
of CKD stages 3–5 in the total population was a third lower than the predicted prevalence 
(Fig 1), even within the VA system with its robust electronic health record and 
implementation of clinical reminders.15 This highlights the ongoing need to optimize 
strategies for appropriate testing and identification of persons with CKD in both the general 
population and high-risk groups.
Another important issue is the availability of laboratory data within the health care system 
for calculation of eGFR. Previous studies have shown that diagnosis claims for CKD, 
although relatively specific, have poor sensitivity for the presence of CKD, potentially 
leading to substantial underestimation of prevalence.12,13 In this study, prevalence estimates 
for CKD based on diagnosis claims alone were 60% lower than those based on eGFR in the 
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VA and M-CARE systems. Even when laboratory results generally are available in the 
health care system, issues with missing values can exist, as we noted in this study within the 
M-CARE system. Although we were able to identify a subset of patients (with UM-PCPs) 
who more consistently had laboratory results available, the data were still incomplete, and 
this likely also contributed to the large gap in observed versus predicted prevalence within 
the M-CARE system. Finally, error also could be introduced from variations in assays and 
lack of standardization for measurement of serum creatinine across laboratories used by 
health care systems.16
The quality of the data for patient characteristics relevant to CKD also is important. Missing 
information for race is a frequent issue in health care system data because it often is not 
routinely or accurately collected. We used a method to impute race from census data on the 
proportion of blacks within the zip code of the patient’s residence, similar to what others 
have done previously.17 This method produces results that are reasonably consistent with 
those based on actual patient-level race information. Comparisons across health care 
systems or with NHANES data also require accurate information for comorbid conditions to 
adequately adjust for differences in population characteristics that may influence the 
prevalence of CKD. Even when some information for comorbid conditions is available, it 
may not be easily comparable across health care systems or compared with NHANES data. 
In the context of this study, for example, the presence of diabetes mellitus was necessarily 
defined differently in NHANES versus M-CARE or VA data (see Table S1). As a result, 
inadequate adjustment for comorbid conditions could have led to errors in estimation of the 
predicted prevalence of CKD.
A final important point relates to the stability of eGFR assessments and the definition of 
CKD. The formal definition of CKD requires a reduced GFR for at least 3 months, although 
this often is not strictly followed, such as with NHANES data, which includes only one 
measurement of serum creatinine.18 When we examined this issue in the VA data, we found 
that for patients with at least 2 serum creatinine measurements 3–6 months apart, nearly 
20% initially identified as stage 3 CKD by eGFR would no longer be classified as having 
CKD based on their second measurement. However, the absolute change in eGFR between 
the 2 assessments was relatively modest (median difference, 6.5 mL/min/1.73 m2) and likely 
of minimal clinical significance, with the change in classification occurring predominantly 
in patients with eGFRs close to the top of the range of their initial CKD stage. Furthermore, 
restricting the sample of patients to those with at least 2 serum creatinine measurements 
introduces a substantial selection bias, tending to include a sicker population of patients. As 
such, it probably is reasonable to base estimates of CKD prevalence in the health care 
system on a single outpatient measurement of serum creatinine. However, users of the data 
should be made aware that the estimates do not meet the strict requirement of chronicity.
In summary, estimation of the prevalence of CKD within health care systems, although 
feasible in principle, remains a challenge due to issues related to the definition of the 
denominator and, in particular, the quality of the data. With the recent legislated emphasis 
on electronic health records, the availability of data relevant to these efforts is likely to 
expand in coming years. Our findings suggest that important areas for improvement for 
electronic health care data include: ensuring the availability and completeness of laboratory 
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results, collecting detailed information for race, and developing consistent definitions for 
recording comorbid conditions. Nevertheless, health care system data in its present state can 
be useful for surveillance relevant to the care of CKD. Within health care systems with 
relatively complete laboratory data, such as in the VA system, we have shown that it is 
possible to derive estimates of prevalence, supplemented with data from NHANES. With 
appropriate analysis and inference, this could be used by health care systems to track the 
burden of CKD within the covered populations over time, to implement disease management 
strategies, or to help assess the potential impact of interventions directed at preventing or 
treating CKD. It also is possible to estimate the magnitude of and trends in potential gaps in 
testing practices for CKD by comparing observed prevalence to predicted estimates based 
on adjusted NHANES data, which can be used by health care systems to direct and monitor 
quality improvement efforts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
The CDC CKD Surveillance System group consists of the following members. Centers for Disease Control and 
Prevention: Desmond Williams, Mark Eberhardt, Kristina Ernst, Nicole Flowers, Linda Geiss, Regina Jordan, Nilka 
Ríos Burrows, Juanita Mondesire, Bernice Moore, Gary Myers, Meda Pavkov, Deborah Rolka, Susan Hailpern, 
Sharon Saydah, Anton Schoolwerth, Rodolfo Valdez, and Paul Eggers (National Institutes of Health); University of 
California San Francisco: Neil Powe (Principal Investigator), Tanushree Banerjee, Kirsten Bibbins-Domingo, L. 
Ebony Boulware, Josef Coresh, Chi-Yuan Hsu; Andrew Levey (Tufts Medical Center and Tufts School of 
Medicine), Charles McCulloch, Edgar R. Miller, III, Laura Plantinga, Annie Rein-Weston, Lesley Stevens (Tufts 
Medical Center and Tufts School of Medicine); University of Michigan: Rajiv Saran (Principal Investigator), 
Brenda Gillespie, Elizabeth Hedgeman, William Herman, Michael Heung, Yi Li, Hal Morgenstern, Bruce Robinson 
(Arbor Research Collaborative for Health), Vahakn Shahinian, Diane Steffick, Anca Tilea, Jerry Yee (Henry Ford 
Health System), and Eric Young (Department of Veterans Affairs).
Support: This work is funded by the Centers for Disease Control and Prevention (CDC), grant 1U58DP003836 for 
the project titled “Establishing a Surveillance System for Chronic Kidney Disease.” This material is the result of 
work partially supported with resources and the use of facilities at the VA Ann Arbor Healthcare System. 
Publication and report contents are solely the responsibility of the authors and do not necessarily represent the 
official views of the CDC, the VA, or the US Government.
REFERENCES
1. CKD Survelillance Team. Establishing a national chronic kidney disease surveillance system for the 
United States. Clin J Am Soc Nephrol. 2010; 5:152–161. [PubMed: 19965534] 
2. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, 
and economic implications. Kidney Int Suppl. 2005; 98:S7–S10. [PubMed: 16108976] 
3. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: a public health 
problem that needs a public health action plan [abstract]. Prev Chronic Dis. 2006; 3:A57. [PubMed: 
16539798] 
4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. 
JAMA. 2007; 298:2038–2047. [PubMed: 17986697] 
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of 
death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305. [PubMed: 
15385656] 
6. Hillestad R, Bigelow J, Bower A, et al. Can electronic medical record systems transform health 
care? Potential health benefits, savings, and costs. Health Aff (Millwood). 2005; 24:1103–1117. 
[PubMed: 16162551] 
Shahinian et al. Page 9
Am J Kidney Dis. Author manuscript; available in PMC 2015 October 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
7. United States Census Bureau. [Accessed February 21, 2013] 2010 Census. http://
factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?
pid_DEC_10_SF2_PCT1&prodType_table.
8. Maynard C, Chapko MK. Data resources in the Department of Veterans Affairs. Diabetes Care. 
2004; 27(suppl 2):B22–B26. [PubMed: 15113778] 
9. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. 
Ann Intern Med. 2009; 150:604–612. [PubMed: 19414839] 
10. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: 
evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 suppl 1(2):S1–S266. 
[PubMed: 11904577] 
11. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, 
renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc 
Nephrol. 2005; 16:489–495. [PubMed: 15590763] 
12. Winkelmayer WC, Schneeweiss S, Mogun H, et al. Identification of individuals with CKD from 
Medicare claims data: a validation study. Am J Kidney Dis. 2005; 46:225–232. [PubMed: 
16112040] 
13. Kern EF, Maney M, Miller DR, et al. Failure of ICD-9-CM codes to identify patients with 
comorbid chronic kidney disease in diabetes. Health Serv Res. 2006; 41:564–580. [PubMed: 
16584465] 
14. O’Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney 
disease: one size for all ages? J Am Soc Nephrol. 2006; 17:846–853. [PubMed: 16452492] 
15. Patel TG, Pogach LM, Barth RH. CKD screening and management in the Veterans Health 
Administration: the impact of system organization and an innovative electronic record. Am J 
Kidney Dis. 2009; 53(suppl 3):S78–S85. [PubMed: 19231765] 
16. Miller WG. Estimating glomerular filtration rate. Clin Chem Lab Med. 2009; 47:1017–1019. 
[PubMed: 19728841] 
17. Guessous I, McClellan W, Vupputuri S, Wasse H. Low documentation of chronic kidney disease 
among high-risk patients in a managed care population: a retrospective cohort study. BMC 
Nephrol. 2009; 10:25. [PubMed: 19758452] 
18. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney 
disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). 
Kidney Int. 2005; 67:2089–2100. [PubMed: 15882252] 
Shahinian et al. Page 10
Am J Kidney Dis. Author manuscript; available in PMC 2015 October 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Observed versus predicted prevalence of chronic kidney disease (CKD) stages 3–5 in the M-
CARE and Veterans Affairs (VA) health care systems. Predicted prevalence was derived 
from a logistic regression model fitted using the National Health and Nutrition Examination 
Survey (NHANES) 2005–2006 data set to predict the presence of CKD stages 3–5 based on 
age, race (non-Hispanic black vs nonblack), diabetes mellitus, hypertension, anemia, and 
sex. The coefficients from this model were used to produce estimates of the prevalence of 
CKD within the VA and M-CARE cohorts based on the respective characteristics of those 
populations. Observed and predicted prevalence are shown for both the population tested for 
serum creatinine (Tested Population) and those not tested (Untested Population). The 
predicted prevalence presented for the total population is a combination of the observed 
prevalence in the tested population and the prevalence in the untested population based on 
the NHANES model. The vertical thin bars represent 95% confidence intervals.
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Table 1
Characteristics of the VA Health System, M-CARE, and NHANES 2005–2006 Populations
M-CARE
NHANES
2005–2006 (N = 4,107)
VA
(N = 203,820)
Non–UM-PCP
(n = 76,508)
UM-PCP
(n = 41,957)
Age (y) 47.3 ± 0.7 64.0 ± 14.9 41.2 ± 11.8 41.7 ± 11.9
Age category
  20–29 y 16.8 2.5 19.4 19.1
  30–39 y 18.7 4.2 26.1 25.4
  40–49 y 22.2 9.8 28.4 27.0
  50–59 y 18.6 23.8 19.6 21.2
  60–69 y 11.4 20.3 6.2 6.8
  ≥70 y 12.3 39.4 0.5 0.4
Male sex 49.5 95.0 45.5 42.1
Race
  Non-Hispanic white 72.9 41.1 NA NA
  Non-Hispanic black 10.9 8.1 NA NA
  Hispanica 11.1a 3.3 NA NA
  Other/unknown 5.1 47.6 NA NA
Diabetes mellitus 9.6 24.1 9.4 5.4
Hypertension 40.0 65.3 20.8 12.3
Note: Values for categorical variables are given as percentages; values for age, as mean ± standard deviation.
Abbreviations and definitions: M-CARE, a managed care health plan in the Southeast Michigan region owned and operated by UM Health System 
until 2006; NA, not available; NHANES, National Health and Nutrition Examination Survey; PCP, primary care physician; VA, Veterans Affairs 
health care system; UM, University of Michigan.
a
The National Center for Health Statistics recommends keeping Mexican American Hispanic and other Hispanic categories separate for reporting 
purposes for NHANES surveys prior to 2007, but these categories were collapsed for comparability to the VA database.
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Table 2
Proportion of Population Who Underwent Testing for Serum Creatinine
M-CARE
VA Non–UM-PCP UM-PCP Only
Overall 75.8 (75.6–76.0) 41.3 (41.0–41.7) 36.6 (36.2–37.1)
Age category
  20–29 y 51.3 (49.9–52.7) 25.2 (24.5–25.9) 21.6 (20.7–22.5)
  30–39 y 60.8 (59.7–61.8) 34.1 (33.4–34.8) 27.1 (26.3–28.0)
  40–49 y 68.7 (68.0–69.3) 43.6 (42.9–44.3) 38.0 (37.1–38.9)
  50–59 y 78.9 (78.5–79.2) 55.7 (54.9–56.5) 51.3 (50.3–52.3)
  60–69 y 81.8 (81.4–82.2) 64.7 (63.3–66.1) 60.6 (58.8–62.4)
  ≥70 y 75.8 (75.5–76.1) 61.8 (56.7–66.9) 74.1 (67.6–80.7)
Sex
  Male 76.1 (75.9–76.3) 42.1 (41.6–42.6) 37.6 (36.9–38.3)
  Female 70.3 (69.4–71.2) 40.6 (40.2–41.1) 35.9 (35.3–36.5)
Race
  Non-Hispanic white 82.0 (81.8–82.3) NA NA
  Non-Hispanic black 79.4 (78.7–80.0) NA NA
  Hispanica 83.1 (82.2–84.0) NA NA
  Other/unknown 69.4 (69.1–69.6) NA NA
Diabetes mellitus
  Yes 88.7 (88.4–89.0) 78.0 (77.1–79.0) 79.1 (77.4–80.8)
  No 71.7 (71.5–71.9) 37.5 (37.1–37.9) 34.2 (33.7–34.7)
Hypertension
  Yes 84.6 (84.4–84.8) 72.6 (71.9–73.3) 77.5 (76.3–78.6)
  No 59.3 (58.9–59.6) 33.1 (32.7–33.4) 30.9 (30.4–31.4)
Note: Based on available laboratory results or claims in M-CARE and the VA health system. Values are given as percentage tested (95% 
confidence interval).
Abbreviations and definitions: M-CARE, a managed care health plan in the Southeast Michigan region owned and operated by UM Health System 
until 2006; NA, not available; PCP, primary care physician; VA, Veterans Affairs health care system; UM, University of Michigan.
a
The National Center for Health Statistics recommends keeping Mexican American Hispanic and other Hispanic categories separate for reporting 
purposes for NHANES surveys prior to 2007, but these categories were collapsed for comparability to the VA database.
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Table 4
Stage of CKD Based on Second Versus First eGFR Measurement
CKD Stage at Second eGFR
CKD Stage at First eGFR eGFR >60 mL/min/1.73 m2 CKD Stage 3 CKD Stage 4 CKD Stage 5
eGFR >60 mL/min/1.73 m2 92.64 7.23 0.11 0.01
CKD stage 3 19.68 76.97 3.31 0.04
CKD stage 4 3.10 26.83 65.63 4.43
CKD stage 5 0 6.06 18.18 75.76
Note: Among patients with multiple serum creatinine measurements in the Veterans Affairs health care system, the second measurement occurred 
3–6 months after first measurement. Values are given as percentages.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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